UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) February 28, 2018



Cross Country Healthcare, Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or Other Jurisdiction of Incorporation)

0-33169 (Commission File Number)

13-4066229 (I.R.S. Employer Identification No.)

5201 Congress Avenue, Suite 100B, Boca Raton, FL 33487 (Address of Principal Executive Office) (Zip Code)

(561) 998-2232

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-	K filing is intended to simultaneou	ısly satisfy the filing obliş	gation of the registrant
under any of the following provisions:			

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Emerging

revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [

growth company [] If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or

Section 2 - Financial Information

Item 2.02 Results of Operations and Financial Condition

(a) On February 28, 2018, Cross Country Healthcare, Inc. ("the Company") issued a press release announcing results for the fourth quarter and full year ended December 31, 2017, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K. This information is being furnished under Item 2.02 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of such section.

Section 7 – Regulation FD

Item 7.01 Regulation FD Disclosure

Incorporated by reference is a press release issued by the Company on February 28, 2018, which is attached hereto as Exhibit 99.1. This information is being furnished under Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of such section.

Section 9 – Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit Description

99.1 Press Release issued by the Company on February 28, 2018

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Dated: February 28, 2018

CROSS COUNTRY HEALTHCARE, INC.

By: /s/ Christopher R. Pizzi

Christopher R. Pizzi

SVP & Chief Financial Officer

Cross Country Healthcare Announces Fourth Quarter and Full Year 2017 Financial Results

BOCA RATON, Fla.--(BUSINESS WIRE)--February 28, 2018--Cross Country Healthcare, Inc. (the "Company") (NASDAQ: CCRN) today announced financial results for its fourth quarter and full year ended December 31, 2017.

FINANCIAL HIGHLIGHTS:

Dollars in thousands, except per share amounts.

Bonars in modsands, except per smare amounts.	Q4 2017	Variance Q4 2017 vs Q4 2016	Full Year 2017	Variance 2017 vs 2016
Revenue	\$219,674	(1)%	\$865,048	4%
Gross profit margin*	26.5%	60 bps	26.4%	(20) bps
Net income attributable to common shareholders	\$27,950	455%	\$37,513	371%
Diluted EPS	\$0.77	\$1.01	\$1.01	\$0.86
Adjusted EBITDA*	\$12,301	2%	\$43,403	(3)%
Adjusted EPS*	\$0.17	\$(0.03)	\$0.61	\$(0.08)
Cash flows from operations	\$16,803	891%	\$45,508	51%

^{*} Refer to accompanying tables and discussion of Non-GAAP financial measures below.

The Company experienced weaker than expected results in the fourth quarter of 2017 primarily in its Nurse and Allied Staffing business with fewer overall placements and a lower renewal rate. The Company also experienced a higher than expected reduction in premium rate business, as well as greater disruptive effects from Hurricane Irma on fourth quarter placements. While the Company expects some of the impact associated with lower renewal rate and premium rate business to continue to affect results in the first quarter of 2018, it believes these pressures are ultimately short-term in nature, the overall trends for the business are strong, and performance will improve as it moves further into fiscal year 2018. Already, in the first quarter, the Company is seeing an uptick in its renewal rate and an increase in orders. The Company also expects to see additional improvement in its Advantage RN business throughout 2018, which it believes will continue to support higher capture rates within its Managed Service Programs and support its long-term strategy.

"Cross Country has experienced tremendous growth over the last four years and we expect to see growth continue as we progress into 2018, led by our high growth, high margin education healthcare staffing business," said CEO William J. Grubbs, "While we expect near-term pressures on top-line growth to dissipate, management has also moved decisively to focus attention on improving costs and operational excellence, as demonstrated by the recent changes to our organizational structure, including the creation of a new Chief Operating Officer role, which we believe will drive greater focus, accountability, and agility in our decision-making and overall performance."

Fourth quarter consolidated revenue was \$219.7 million, a decrease of 1% year-over-year and 4% sequentially. Consolidated gross profit margin was 26.5%, up 60 basis points year-over-year and flat sequentially. Net income attributable to common shareholders was \$28.0 million, impacted by noncash items including nonrecurring net income tax benefits of \$34.5 million, partly offset by Physician Staffing impairment charges of \$14.4 million (\$12.1 million after taxes), compared to a net loss of \$7.9 million in the prior year, including a noncash loss on the derivative liability of \$14.2 million. Diluted EPS was \$0.77 per share compared to a loss of \$0.24 per share in the prior year. Adjusted EBITDA was \$12.3 million or 5.6% of revenue, as compared with \$12.0 million or 5.4% of revenue in the prior year. Adjusted EPS was \$0.17 in the current quarter as compared to \$0.20 in the prior year and \$0.23 in the prior quarter.

For the year ended December 31, 2017, consolidated revenue was \$865.0 million, an increase of 4% year-over-year. Consolidated gross profit margin was 26.4%, down 20 basis points year-over-year. Net income attributable to common shareholders was \$37.5 million, compared to \$8.0 million in the prior year. Adjusted EBITDA was \$43.4 million or 5.0% of revenue, as compared with \$44.7 million or 5.4% of revenue in the prior year. Adjusted EPS was \$0.61 compared to \$0.69 in the prior year.

Fourth quarter and full year results were impacted by noncash items including a \$42.5 million income tax benefit resulting from the reversal of substantially all of the Company's valuation allowances on its net deferred tax assets, \$14.4 million of impairment charges related to Physician Staffing, and \$8.0 million of income tax expense attributable to the Company's re-measurement of its deferred tax assets under the 2017 Tax Cuts and Jobs Act. Given the significant complexity of the new tax legislation, the Company's estimate of the impact may be refined during 2018.

Quarterly Business Segment Highlights

Nurse and Allied Staffing

Revenue from Nurse and Allied Staffing was \$193.7 million, a slight decrease from the prior year, and a decrease of 3% sequentially. Contribution income was \$19.2 million, up from \$18.1 million in the prior year. Average field FTEs increased to 7,521 from 7,156 in the prior year. Revenue per FTE per day was \$280 compared to \$295 in the prior year, primarily reflecting a change in the mix of business.

Physician Staffing

Revenue from Physician Staffing was \$22.6 million, a decrease of 9% year-over-year and sequentially, with the year-over-year decrease due to changes in mix and the sequential decline due to volume. Contribution income was \$1.0 million, down from \$2.3 million in the prior year. Total days filled were 15,115 as compared with 14,521 in the prior year, with growth in advanced practices partly offset by declines in physician specialties. Revenue per day filled was \$1,489 as compared with \$1,599 in the prior year, representing the impact of a shift in mix of specialties within physician staffing and growth in advanced practices, which generally have a lower daily bill rate.

Other Human Capital Management Services

Revenue from Other Human Capital Management Services was \$3.4 million, a decrease of 8% year-over-year and an increase of 8% sequentially. Contribution loss was \$0.2 million compared to a loss of \$0.3 million in the prior year.

Cash Flow and Balance Sheet Highlights

Cash flow provided by operating activities for the current quarter was \$16.8 million compared to cash used of \$2.1 million in the prior year. Cash flow provided by operating activities for the full year was \$45.5 million compared to \$30.1 million in the prior year. At December 31, 2017, the Company had \$25.5 million in cash and cash equivalents and a \$100.0 million term loan outstanding. There were no borrowings drawn on its \$115.0 million revolving credit facility, and \$21.6 million of letters of credit outstanding, leaving \$93.4 million available for borrowings under the revolving credit facility.

Outlook for First Quarter 2018

The guidance below applies only to management's expectations for the first quarter of 2018. Though the Company does not provide full year guidance, organic growth for the full year and continued margin improvements are expected based on continued favorable market conditions and demand for its services. In addition to the normal operating leverage from anticipated revenue growth, the Company will be undertaking actions to further align its cost structure for improved profitability towards achieving its near-term goal of 8% Adjusted EBITDA margin. For the full year, the Company will also be launching a significant initiative to replace its legacy system supporting its largest business, travel nurse staffing.

	Q1 2018 Range	Year-over-Year Change	Sequential Change
Revenue	\$205 million - \$210 million	(1)% - 1%	(7)% - (4)%
Gross Profit Margin	25.5% - 26.0%	(20) bps - 30 bps	(100) bps - (50) bps
Adjusted EBITDA	\$6 million - \$7 million	(7)% - 8%	(51)% - (43)%
Adjusted EPS	\$0.01 - \$0.03	\$(0.04) - \$(0.02)	\$(0.16) - \$(0.14)

The estimates above are based on current management expectations and, as such, are forward-looking and actual results may differ materially. The quarterly guidance reflects approximately 70 to 80 basis points associated with the annual payroll tax reset. The above ranges do not include the potential impact of any future divestitures, mergers, acquisitions or other business combinations, any impairment charges or valuation allowances, any acquisition-related measurement period adjustments, changes in debt structure, or any material legal or restructuring charges. See accompanying Non-GAAP financial measures and tables below.

INVITATION TO CONFERENCE CALL

The Company will hold its quarterly conference call on Thursday, March 1, 2018, at 9:00 A.M. Eastern Time to discuss its fourth quarter and full year 2017 financial results. This call will be webcast live and can be accessed at the Company's website at www.crosscountryhealthcare.com or by dialing 800-857-6331 from anywhere in the U.S. or by dialing 517-623-4781 from non-U.S. locations - Passcode: Cross Country. A replay of the webcast will be available from March 1, 2018 through March 15, 2018 at the Company's website and a replay of the conference call will be available by telephone by calling 866-357-1431 from anywhere in the U.S. or 203-369-0118 from non-U.S. locations - Passcode: 2018.

ABOUT CROSS COUNTRY HEALTHCARE

Cross Country Healthcare is a national leader in providing innovative healthcare workforce solutions and staffing services. Our solutions leverage our nearly 40 years of expertise and insight to assist clients in solving complex labor-related challenges while maintaining high quality outcomes. We are dedicated to recruiting and placing highly qualified healthcare professionals in virtually every specialty and area of expertise. Our diverse client base includes both clinical and nonclinical settings, servicing acute care hospitals, physician practice groups, outpatient and ambulatory-care centers, nursing facilities, both public schools and charter schools, rehabilitation and sports medicine clinics, government facilities, and homecare. Through our national staffing teams and network of 76 office locations, we are able to place clinicians on travel and per diem assignments, local short-term contracts and permanent positions. We are a market leader in providing flexible workforce management solutions, which include managed services programs (MSP), internal resource pool consulting and development, electronic medical record (EMR) transition staffing, recruitment process outsourcing, predictive modeling and other outsourcing and consultative services. In addition, we provide both retained and contingent placement services for healthcare executives, physicians, and other healthcare professionals.

Copies of this and other news releases as well as additional information about Cross Country Healthcare can be obtained online at www.crosscountryhealthcare.com. Shareholders and prospective investors can also register to automatically receive the Company's press releases, SEC filings and other notices by e-mail.

NON-GAAP FINANCIAL MEASURES

This press release and accompanying financial statement tables reference non-GAAP financial measures. Such non-GAAP financial measures are provided as additional information and should not be considered substitutes for, or superior to, financial measures calculated in accordance with U.S. GAAP. Such non-GAAP financial measures are provided for consistency and comparability to prior year results; furthermore, management believes they are useful to investors when evaluating the Company's performance as they exclude certain items that management believes are not indicative of the Company's operating performance. Pro forma measures, if applicable, are adjusted to include the results of our acquisitions, and exclude the results of divestments, as if the transactions occurred in the beginning of the periods mentioned. Such non-GAAP financial measures may differ materially from the non-GAAP financial measures used by other companies. The financial statement tables that accompany this press release include a reconciliation of each non-GAAP financial measure to the most directly comparable U.S. GAAP financial measure and a more detailed discussion of each financial measure; as such, the financial statement tables should be read in conjunction with the presentation of these non-GAAP financial measures.

FORWARD LOOKING STATEMENT

In addition to historical information, this press release contains statements relating to our future results (including certain projections and business trends) that are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and are subject to the "safe harbor" created by those sections. Forward-looking statements consist of statements that are predictive in nature, depend upon or refer to future events. Words such as "expects", "anticipates", "intends", "plans", "believes", "estimates", "suggests", "appears", "seeks", "will", and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results and performance to be materially different from any future results or performance expressed or implied by these forward-looking statements. These factors include, but are not limited to, the following: our ability to attract and retain qualified nurses, physicians and other healthcare personnel, costs and availability of short-term housing for our travel healthcare professionals, demand for the healthcare services we provide, both nationally and in the regions in which we operate, the functioning of our information systems, the effect of cyber security risks and cyber incidents on our business, the effect of existing or future government regulation and federal and state legislative and enforcement initiatives on our business, our clients' ability to pay us for our services, our ability to successfully implement our acquisition and development strategies, including our ability to successfully integrate acquired businesses and realize synergies from such acquisitions, the effect of liabilities and other claims asserted against us, the effect of competition in the markets we serve, our ability to successfully defend the Company, its subsidiaries, and its officers and directors on the merits of any lawsuit or determine its potential liability, if any, and other factors set forth in Item 1A. "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2016, and our other Securities and Exchange Commission filings made prior to the date hereof.

Although we believe that these statements are based upon reasonable assumptions, we cannot guarantee future results and readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's opinions only as of the date of this press release. There can be no assurance that (i) we have correctly measured or identified all of the factors affecting our business or the extent of these factors' likely impact, (ii) the available information with respect to these factors on which such analysis is based is complete or accurate, (iii) such analysis is correct or (iv) our strategy, which is based in part on this analysis, will be successful. The Company undertakes no obligation to update or revise forward-looking statements. All references to "we", "us", "our", or "Cross Country" in this press release mean Cross Country Healthcare, Inc. and its subsidiaries.

Cross Country Healthcare, Inc. Consolidated Statements of Operations (Unaudited, amounts in thousands, except per share data)

		Three Months Ended							Year Ended			
	December 31,			cember 31,	Sep	otember 30,			De	cember 31,		
		2017		2016		2017		2017		2016		
Revenue from services	\$	219,674	\$	222,523	\$	228,488	\$	865,048	\$	833,537		
Operating expenses:	,	-,-	•	,	•	-,	•	,-	•	,		
Direct operating expenses		161,371		164,890		168,008		636,462		611,802		
Selling, general and administrative expenses		46,253		46,290		47,346		187,435		179,820		
Bad debt expense		746		97		433		1,828		593		
Depreciation and amortization		2,849		2,213		2,849		10,174		9,182		
Acquisition-related contingent consideration (a)		98		107		(605)		44		814		
Acquisition and integration costs (b)		22		78		1,366		1,975		78		
Restructuring costs (c)		302		142		724		1,026		753		
Impairment charges (d)		14,356		_		_		14,356		24,311		
Total operating expenses		225,997		213,817		220,121		853,300		827,353		
Income from operations		(6,323)		8,706		8,367		11,748		6,184		
Other expenses (income):												
Interest expense		1,239		1,428		1,221		4,214		6,106		
Loss (gain) on derivative liability (e)		_		14,165		_		(1,581)		(5,805)		
Loss on early extinguishment of debt (f)		_		_		_		4,969		1,568		
Other income, net		(39)		(87)		(57)		(155)		(230)		
(Loss) income before income taxes		(7,523)		(6,800)		7,203		4,301		4,545		
Income tax (benefit) expense (g)		(35,779)		849		159		(34,501)		(4,186)		
Consolidated net income (loss)		28,256		(7,649)		7,044		38,802		8,731		
Less: Net income attributable to noncontrolling interest in subsidiary		306		235		321		1,289		764		
Net income (loss) attributable to common shareholders	\$	27,950	\$	(7,884)	\$	6,723	\$	37,513	\$	7,967		
Net income (loss) per share attributable to common shareholders - Basic	\$	0.78	\$	(0.24)	\$	0.19	\$	1.07	\$	0.25		
Net income (1055) per share attributable to common shareholders - Dasic	Ψ	0.70	Ψ	(0.24)	Ψ	0.13	Ψ	1.07	Ψ	0.23		
Net income (loss) per share attributable to common shareholders - Diluted	\$	0.77	\$	(0.24)	\$	0.19	\$	1.01	\$	0.15		
Weighted average common shares outstanding:												
Basic		35,760		32,263		35,748		35,018		32,132		
Diluted (h)		36,129		32,263		36,036		36,166		36,246		
		·										

Cross Country Healthcare, Inc. Reconciliation of Non-GAAP Financial Measures (Unaudited, amounts in thousands)

December 31, Dece
Adjusted EBITDA: (i) 27,950 \$ (7,884) \$ (37.23) \$ 37,513 \$ 7,967 Net income (loss) attributable to common shareholders \$ 27,950 \$ (7,884) \$ (32.21) 4,214 4,6106 4,6106 1,239 1,428 1,221 4,214 4,6106 1,6106 1,000 1,239 1,428 1,221 4,214 4,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106 1,6106
Net income (loss) attributable to common shareholders \$ 27,950 \$ (7,884) \$ 6,723 \$ 37,513 \$ 7,967 Interest expense 1,239 1,428 1,221 4,214 6,106 Income ax (benefit) expense (g) (35,779) 849 159 34,501 (4,166) Depreciation and amortization 2,849 2,213 2,849 10,174 9,182 Acquisition-related contingent consideration (a) 98 107 (605) 44 814 Acquisition and integration costs (b) 22 78 1,366 1,975 753 Restructuring costs (c) 302 142 724 1,026 753 Inpairment charges (d) 14,356 — — 14,356 24,311 Loss (gain) on derivative liability (e) — 14,165 — 1,581 (5,805) Other income, net 339 877 657 1,581 230 Equity compensation 997 765 1,068 4,089 3,379 Net income attributable to noncontrolling intere
Interest expense
Income tax (benefit) expense (g)
Depreciation and amortization 2,849 2,213 2,849 10,174 9,182 Acquisition-related contingent consideration (a) 98 107 (605) 44 814 Acquisition and integration costs (b) 22 78 1,366 1,975 78 Restructuring costs (c) 302 142 724 1,026 753 Impairment charges (d) 14,356 — — 14,556 — 14,556 24,311 Loss (gain) on derivative liability (e) — 14,165 — 4,969 1,586 Other income, net (39) (87) (57) (155) 230 Equity compensation 997 765 1,068 4,080 3,379 Net income attributable to noncontrolling interest in subsidiary 306 235 321 1,289 764 Adjusted EBITDA (i) \$2,300 \$2,301 \$1,360 \$3,403 \$4,470 Non-GARP adjustments - pretax: *2,950 \$7,884 \$6,723 \$3,513 \$7,967
Acquisition-related contingent consideration (a) 98 107 (605) 44 814 Acquisition and integration costs (b) 22 78 1,366 1,975 78 Restructuring costs (c) 302 142 724 1,026 753 Impairment charges (d) 14,356 — — 14,356 2,311 Loss (gain) on derivative liability (e) — 14,165 — 4,969 1,568 Other income, net (33) (87) (57) (155) 230 Cuity compensation 997 765 1,068 4,089 3,379 Net income attributable to noncontrolling interest in subsidiary 306 235 321 1,289 766 Adjusted EBITDA (i) * 12,301 * 13,769 * 3,470 *** Type of the income (loss) attributable to common shareholders * 27,950 * 7,884 * 6,723 * 3,751 * 7,967 *** Type of the income (loss) attributable to common shareholders
Acquisition and integration costs (b) 22 78 1,366 1,975 78 Restructuring costs (c) 302 142 724 1,026 753 Impairment charges (d) 14,356 — — 14,356 24,311 Loss (gain) on derivative liability (e) — 14,165 — (1,581) (5,805) Loss on early extinguishment of debt (f) — — — 4,969 1,568 Other income, net (39) (87) (57) (155) (230) Equity compensation 997 765 1,068 4,080 3,379 Net income attributable to noncontrolling interest in subsidiary 306 235 321 1,280 764 Adjusted EPS: (j) *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** ***
Restructuring costs (c) 302 142 724 1,026 753 Impairment charges (d) 14,356 — — 14,356 24,311 Loss (gain) on derivative liability (e) — 14,165 — (1,581) (5,805) Loss on early extinguishment of debt (f) — — — 4,969 1,568 Other income, net (339) (87) (57) (155) (230) Equity compensation 997 765 1,068 4,080 3,379 Net income attributable to noncontrolling interest in subsidiary 306 235 321 1,289 764 Adjusted EPS: (j) 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000<
Impairment charges (d) 14,356 — — 14,356 24,311 Loss (gain) on derivative liability (e) — 14,165 — (1,581) (5,805) Loss on early extinguishment of debt (f) — — — 4,969 1,568 Other income, net (33) (87) (57) (155) (230) Equity compensation 997 765 1,068 4,080 3,379 Net income attributable to noncontrolling interest in subsidiary 306 235 321 1,289 764 Adjusted EPS: (j) S 12,301 \$ 12,011 \$ 13,769 \$ 43,403 \$ 44,701 Adjusted EPS: (j) Numerator: S 27,950 \$ (7,884) \$ 6,723 \$ 37,513 \$ 7,967 Non-GAAP adjustments - pretax: S 27,950 \$ (7,884) \$ 6,723 \$ 37,513 \$ 7,967 Non-GAAP adjustments - pretax: S 27,950 \$ 10,784 \$ 6,723 \$ 37,513 \$ 7,967 Acquisition-related contingent consideration (a)
Loss (gain) on derivative liability (e) — 14,165 — (1,581) (5,805) Loss on early extinguishment of debt (f) — — — 4,969 1,568 Other income, net (39) (87) (57) (155) (230) Equity compensation 997 765 1,068 4,080 3,379 Net income attributable to noncontrolling interest in subsidiary 306 235 321 1,289 764 Adjusted EBITDA (i) * 12,301 * 13,769 * 43,403 * 44,701 Numerator: Consolidated net income (loss) attributable to common shareholders * 27,950 * 7,884 * 6,723 * 37,513 * 7,967 Non-GANP adjustments - pretax: Acquisition-related contingent consideration (a) 98 107 (605) 44 814 Acquisition and integration costs (b) 22 78 1,366 1,975 78 Restructuring costs (c) 302 142
Loss on early extinguishment of debt (f) — — — 4,969 1,568 Other income, net (39) (87) (57) (155) (230) Equity compensation 997 765 1,068 4,080 3,379 Net income attributable to noncontrolling interest in subsidiary 306 235 321 1,289 764 Adjusted EPS: (j) *** Use of the properties of th
Other income, net (39) (87) (57) (155) (230) Equity compensation 997 765 1,068 4,080 3,379 Net income attributable to noncontrolling interest in subsidiary 306 235 321 1,289 764 Adjusted EPS: (j) \$ 12,301 \$ 12,011 \$ 13,769 \$ 43,403 \$ 44,701 Consolidated be income (loss) attributable to common shareholders \$ 27,950 \$ (7,884) \$ 6,723 \$ 37,513 \$ 7,967 Non-GAAP adjustments - pretax: Acquisition-related contingent consideration (a) 98 107 (605) 44 814 Acquisition and integration costs (b) 22 78 1,366 1,975 78 Restructuring costs (c) 302 142 724 1,026 753 Impairment charges (d) 14,356 - - - 14,356 24,311
Equity compensation 997 765 1,068 4,080 3,379 Net income attributable to noncontrolling interest in subsidiary 306 235 321 1,289 764 Adjusted EBITDA (i) \$ 12,301 \$ 12,011 \$ 13,769 \$ 43,403 \$ 44,701 Adjusted EPS: (j) Numerator: \$ 27,950 \$ (7,884) \$ 6,723 \$ 37,513 \$ 7,967 Non-GAAP adjustments - pretax: \$ 27,950 \$ (7,884) \$ 6,723 \$ 37,513 \$ 7,967 Acquisition-related contingent consideration (a) 98 107 (605) 44 814 Acquisition and integration costs (b) 22 78 1,366 1,975 78 Restructuring costs (c) 302 142 724 1,026 753 Impairment charges (d) 14,356 - - - 14,356 24,311
Net income attributable to noncontrolling interest in subsidiary 306 235 321 1,289 764 Adjusted EBITDA (i) \$ 12,301 \$ 12,011 \$ 13,769 \$ 43,403 \$ 44,701 Adjusted EPS: (j) Numerator: \$ 27,950 \$ (7,884) \$ 6,723 \$ 37,513 \$ 7,967 Consolidated net income (loss) attributable to common shareholders \$ 27,950 \$ (7,884) \$ 6,723 \$ 37,513 \$ 7,967 Non-GAAP adjustments - pretax: \$ 28,000 \$ 107 \$ (605) 44 814 Acquisition related contingent consideration (a) 98 107 \$ (605) 44 814 Acquisition and integration costs (b) 22 78 1,366 1,975 78 Restructuring costs (c) 302 142 724 1,026 753 Impairment charges (d) 14,356 - - - 14,356 24,311
Adjusted EBITDA (i) \$ 12,301 \$ 12,011 \$ 13,769 \$ 43,403 \$ 44,701 Adjusted EPS: (j) Numerator: \$ 27,950 \$ (7,884) \$ 6,723 \$ 37,513 \$ 7,967 Consolidated net income (loss) attributable to common shareholders \$ 27,950 \$ (7,884) \$ 6,723 \$ 37,513 \$ 7,967 Non-GAAP adjustments - pretax: Acquisition-related contingent consideration (a) 98 107 (605) 44 814 Acquisition and integration costs (b) 22 78 1,366 1,975 78 Restructuring costs (c) 302 142 724 1,026 753 Impairment charges (d) 14,356 - - 14,356 24,311
Adjusted EPS: (j) Numerator: Second lidated net income (loss) attributable to common shareholders \$ 27,950 \$ (7,884) \$ 6,723 \$ 37,513 \$ 7,967 Non-GAAP adjustments - pretax: 8 107 (605) 44 814 Acquisition related contingent consideration (a) 98 107 (605) 44 814 Acquisition and integration costs (b) 22 78 1,366 1,975 78 Restructuring costs (c) 302 142 724 1,026 753 Impairment charges (d) 14,356 — — 14,356 24,311
Numerator: 27,950 (7,884) 6,723 37,513 7,967 Non-GAAP adjustments - pretax: 8 107 (605) 44 814 Acquisition-related contingent consideration (a) 98 107 (605) 44 814 Acquisition and integration costs (b) 22 78 1,366 1,975 78 Restructuring costs (c) 302 142 724 1,026 753 Impairment charges (d) 14,356 - - - 14,356 24,311
Numerator: 27,950 (7,884) 6,723 37,513 7,967 Non-GAAP adjustments - pretax: 8 107 (605) 44 814 Acquisition-related contingent consideration (a) 98 107 (605) 44 814 Acquisition and integration costs (b) 22 78 1,366 1,975 78 Restructuring costs (c) 302 142 724 1,026 753 Impairment charges (d) 14,356 - - - 14,356 24,311
Consolidated net income (loss) attributable to common shareholders \$ 27,950 \$ (7,884) \$ 6,723 \$ 37,513 \$ 7,967 Non-GAAP adjustments - pretax: Acquisition-related contingent consideration (a) 98 107 (605) 44 814 Acquisition and integration costs (b) 22 78 1,366 1,975 78 Restructuring costs (c) 302 142 724 1,026 753 Impairment charges (d) 14,356 - - - - 14,356 24,311
Non-GAAP adjustments - pretax: 98 107 (605) 44 814 Acquisition-related contingent consideration (a) 98 107 (605) 44 814 Acquisition and integration costs (b) 22 78 1,366 1,975 78 Restructuring costs (c) 302 142 724 1,026 753 Impairment charges (d) 14,356 14,356 24,311
Acquisition-related contingent consideration (a) 98 107 (605) 44 814 Acquisition and integration costs (b) 22 78 1,366 1,975 78 Restructuring costs (c) 302 142 724 1,026 753 Impairment charges (d) 14,356 — — 14,356 24,311
Acquisition-related contingent consideration (a) 98 107 (605) 44 814 Acquisition and integration costs (b) 22 78 1,366 1,975 78 Restructuring costs (c) 302 142 724 1,026 753 Impairment charges (d) 14,356 — — 14,356 24,311
Acquisition and integration costs (b) 22 78 1,366 1,975 78 Restructuring costs (c) 302 142 724 1,026 753 Impairment charges (d) 14,356 — — 14,356 24,311
Restructuring costs (c) 302 142 724 1,026 753 Impairment charges (d) 14,356 — — 14,356 24,311
Impairment charges (d) 14,356 — 14,356 24,311
Loss (gain) on derivative liability (e) $-$ 14,165 $-$ (1,581) (5,805)
Loss on early extinguishment of debt (f) — — 4,969 1,568
Nonrecurring income tax adjustments (34,476) — (34,476) —
Tax impact of non-GAAP adjustments (k) (2,211) — — (2,211) (7,036)
Adjusted net income attributable to common shareholders - non-GAAP \$ 6,041 \$ 6,608 \$ 8,208 \$ 21,615 \$ 22,650
Adjusted it it income distribution is included in 16.12.11
Denominator:
Weighted average common shares - basic, GAAP 35,760 32,263 35,748 35,018 32,132
Dilutive impact of share-based payments 369 557 288 425 593
Adjusted weighted average common shares - diluted, non-GAAP 36,129 32,820 36,036 35,443 32,725
Aujusteu weigineu average Common siiares - unuteu, non-daar 30,129 32,020 30,030 33,443 32,723
Reconciliation: (j)
Diluted EPS, GAAP \$ 0.77 \$ (0.24) \$ 0.19 \$ 1.01 \$ 0.15
Non-GAAP adjustments - pretax:
Acquisition-related contingent consideration (a) — — (0.02) — 0.03
Acquisition and integration costs (b) — 0.04 0.06 —
Restructuring costs (c) 0.01 0.01 0.02 0.03 0.03
Impairment charges (d) 0.40 — 0.40 0.74
Loss (gain) on derivative liability (e) — 0.43 — (0.05) (0.18)
Loss on early extinguishment of debt (f) — — — 0.14 0.05
Nonrecurring income tax adjustments (0.95) — (0.97) — (0.97)
Tax impact of non-GAAP adjustments (k) (0.06) — — (0.06) (0.22)
Adjustment for change in dilutive shares
Adjusted EPS, non-GAAP (j) \$ 0.17 \$ 0.20 \$ 0.61 \$ 0.69

Cross Country Healthcare, Inc. Consolidated Balance Sheets (Unaudited, amounts in thousands)

December 31,

December 31,

	2017			2016		
Assets Current assets:						
Cash and cash equivalents	\$	25,537	\$	20,630		
Accounts receivable, net	Ψ	173,603	Ψ	173,620		
Prepaid expenses		5,287		6,126		
Insurance recovery receivable		3,497		3,037		
Other current assets		963		2,198		
Total current assets		208,887		205,611		
Property and equipment, net		14,086		12,818		
Goodwill, net		117,589		79,648		
Trade names, indefinite-lived		26,702		35,402		
Other intangible assets, net		60,976		36,835		
Non-current deferred tax assets		20,219				
Other non-current assets		19,228		18,064		
Total assets	\$	467,687	\$	388,378		
Total discis	<u> </u>	407,007	Ψ	300,370		
Liabilities and Stockholders' Equity						
Current liabilities:						
Accounts payable and accrued expenses	\$	50,597	\$	58,850		
Accrued employee compensation and benefits	Ψ	34,271	Ψ	33,243		
Current portion of long-term debt and capital lease obligations		6,875		2,250		
Other current liabilities		2,845		2,749		
Total current liabilities		94,588		97,092		
Long-term debt and capital lease obligations		94,366		84,750		
Non-current deferred tax liabilities		105		13,154		
Long-term accrued claims		28,757		28,870		
Contingent consideration		5,088		5,301		
Other long-term liabilities		9,171		7,409		
Total liabilities		229,968		236,576		
Total nabilities		229,900		230,370		
Commitments and contingencies						
Stockholders' equity:						
Common stock		4		3		
Additional paid-in capital		305,362		256,570		
Accumulated other comprehensive loss		(1,166)		(1,241)		
Accumulated other comprehensive loss Accumulated deficit		(67,111)		(1,241) (104,089)		
		237,089		151,243		
Total Cross Country Healthcare, Inc. stockholders' equity Nancontrolling interest in subsidiary		237,089 630		151,243 559		
Noncontrolling interest in subsidiary						
Total stockholders' equity	Ф.	237,719	Ф.	151,802		
Total liabilities and stockholders' equity	\$	467,687	\$	388,378		

Cross Country Healthcare, Inc. Segment Data (l) (Unaudited, amounts in thousands)

	Three Months Ended									Year-over- Year	Sequential
	De	cember 31,	% of		ecember 31,	% of	September 30,		% of	% change	% change
		2017	Total		2016	Total		2017	Total	Fav (Unfav)	Fav (Unfav)
Revenue from services:											
Nurse and Allied Staffing	\$	193,740	88%	\$	194,050	87%	\$	200,492	88%	(0.2)%	(3.4)%
Physician Staffing		22,555	10%		24,813	11%		24,871	11%	(9.1)%	(9.3)%
Other Human Capital Management Services		3,379	2%	_	3,660	2%		3,125	1%	(7.7)%	8.1%
	\$	219,674	100%	\$	222,523	100%	\$	228,488	100%	(1.3)%	(3.9)%
Contribution income: (m)											
Nurse and Allied Staffing	\$	19,188		\$	18,115		\$	20,663		5.9%	(7.1)%
Physician Staffing		1,049			2,262			1,340		(53.6)%	(21.7)%
Other Human Capital Management Services		(157)	_		(339)	_		(1)	_	53.7%	NM
		20,080			20,038			22,002		0.2%	(8.7)%
Unallocated corporate overhead (n)		8,776			8,792			9,301		0.2%	5.6%
Depreciation and amortization		2,849			2,213			2,849		(28.7)%	%
Acquisition-related contingent consideration (a)		98			107			(605)		8.4%	(116.2)%
Acquisition and integration costs (b)		22			78			1,366		71.8%	98.4%
Restructuring costs (c)		302			142			724		(112.7)%	58.3%
Impairment charges (d)		14,356		_		_	_		-	(100.0)%	(100.0)%
Income from operations	\$	(6,323)	=	\$	8,706	=	\$	8,367	=	(172.6)%	(175.6)%
			Year	Ended	i						
	De	cember 31,	% of	De	ecember 31,	% of					
		2017	Total		2016	Total					
Revenue from services:											
Nurse and Allied Staffing	\$	758,267	88%	\$	721,486	86%				5.1%	
Physician Staffing		93,610	11%		98,283	12%				(4.8)%	
Other Human Capital Management Services		13,171	1%		13,768	2%				(4.3)%	
	\$	865,048	100%	\$	833,537	100%				3.8%	
Contribution income: (m)											
Nurse and Allied Staffing	\$	73,614		\$	71,992					2.3%	
Physician Staffing		5,256			8,265					(36.4)%	
Other Human Capital Management Services		(357)	_		(535)					33.3%	
		78,513			79,722					(1.5)%	
Unallocated corporate overhead (n)		39,190			38,400					(2.1)%	
Depreciation and amortization		10,174			9,182					(10.8)%	
Acquisition-related contingent consideration (a)		44			814					94.6%	
Acquisition and integration costs (b)		1,975			78					NM	
Restructuring costs (c)		1,026			753					(36.3)%	
Impairment charges (d)	_	14,356	-	_	24,311	-				40.9%	
Income from operations	\$	11,748	=	\$	6,184	=				90.0%	
NM-Not meaningful.											

Cross Country Healthcare, Inc. Other Financial Data (Unaudited)

	Three Months Ended							Year Ended				
	December 31, 2017		December 31, 2016		September 30, 2017		December 31, 2017		De	cember 31, 2016		
Net cash (used in) provided by operating activities (in thousands)	\$	16,803	\$	(2,124)	\$	3,180	\$	45,508	\$	30,145		
Consolidated gross profit margin (o)		26.5%		25.9%		26.5%		26.4 %)	26.6%		
Nurse and Allied Staffing statistical data: FTEs (p) Average Nurse and Allied Staffing revenue per FTE per day (q)	\$	7,521 280	\$	7,156 295	\$	7,706 283	\$	7,397 281	\$	6,953 284		
Physician Staffing statistical data: Days filled (r) Revenue per day filled (s)	\$	15,115 1,489	\$	14,521 1,599	\$	15,777 1,562	\$	61,148 1,549	\$	62,482 1,549		

- (a) Acquisition-related contingent consideration represents the fair value and accretion adjustments to the contingent consideration liabilities for the Mediscan acquisition that closed on October 30, 2015 and the US Resources Healthcare acquisition that closed on December 1, 2016.
- (b) Acquisition and integration costs are primarily related to legal and advisory fees for the Advantage RN, LLC acquisition that closed effective July 1, 2017.
- (c) Restructuring costs related to severance and lease consolidations incurred as part of our separate and discrete cost savings initiatives.
- (d) Impairment charges (noncash) of \$14.4 million (\$12.1 million after taxes) related to goodwill and trade names of Physician Staffing are included in the three months and year ended December 31, 2017. The year ended December 31, 2016 includes noncash impairment charges of \$24.3 million (\$17.3 million after taxes) related to Physician Staffing goodwill, trade names, and customer relations.
- (e) Loss (gain) on derivative liability represents the change in the fair value of embedded features of our Convertible Notes up until their repayment.
- (f) Loss on early extinguishment of debt for the year ended December 31, 2017 is related to the Company's settlement of its convertible notes on March 17, 2017. Loss on early extinguishment of debt for the year ended December 31, 2016 relates to the write-off of unamortized debt discount and issuance costs as well as transaction fees and expenses related to the extinguishment of the Company's subordinated term loan.
- (g) Income tax benefit for the three months and year ended December 31, 2017 is primarily a result of a release of valuation allowances on the Company's deferred tax assets totaling \$42.5 million, offset by an \$8.0 million reduction in the Company's net deferred tax assets (relating to the impact from the Tax Cuts and Jobs Act).
- (h) When applying the if-converted method to its Convertible Notes, 723,519 shares were included in diluted weighted average shares for the year ended December 31, 2017 and 3,521,126 shares were included for the year ended December 31, 2016.
- (i) Adjusted EBITDA, a non-GAAP (Generally Accepted Accounting Principles) financial measure, is defined as net income attributable to common shareholders before interest expense, income tax (benefit) expense, depreciation and amortization, acquisition-related contingent consideration, acquisition and integration costs, restructuring costs, impairment charges, loss (gain) on derivative liability, loss on early extinguishment of debt, other income, net, equity compensation, and includes net income attributable to noncontrolling interest in subsidiary. Adjusted EBITDA should not be considered a measure of financial performance under GAAP. Management presents Adjusted EBITDA because it believes that Adjusted EBITDA is a useful supplement to net income attributable to common shareholders as an indicator of operating performance. Management uses Adjusted EBITDA for planning purposes and as one performance measure in its incentive programs for certain members of its management team. Adjusted EBITDA, as defined, closely matches the operating measure typically used in the Company's credit facilities in calculating various ratios. Adjusted EBITDA Margin is calculated by dividing Adjusted EBITDA by the Company's consolidated revenue.
- (j) Adjusted EPS, a non-GAAP financial measure, is defined as net income (loss) attributable to common shareholders per diluted share before the diluted EPS impact of acquisition-related contingent considertion, acquisition and integration costs, restructuring costs, impairment charges, loss (gain) on derivative liability, loss on early extinguishment of debt, and non-recurring income tax adjustments. Adjusted EPS should not be considered a measure of financial performance under GAAP. Management presents Adjusted EPS because it believes that Adjusted EPS is a useful supplement to its reported EPS as an indicator of operating performance. Management uses Adjusted EPS as one performance measure in its annual cash incentive program for certain members of its management team. Management believes it provides a more useful companison of the Company's underlying business performance from period to period and is more representative of the future earnings capacity of the Company.
- (k) Due to the Company previously maintaining a full valuation allowance, there was no tax impact on non-GAAP measures with the exception of the impact of impairment charges on goodwill.
- (1) Segment data provided is in accordance with the Segment Reporting Topic of the FASB ASC.
- (m) Contribution income is defined as income or loss from operations before depreciation and amortization, acquisition-related contingent consideration, acquisition and integration costs, restructuring costs, impairment charges, and corporate expenses not specifically identified to a reporting segment. Contribution income is a financial measure used by management when assessing segment performance.
- (n) Unallocated corporate overhead includes corporate compensation and benefits, and general and administrative expenses including rent and utilities, computer supplies and expenses, insurance, professional expenses, corporate-wide projects (initiatives), and public company expense.
- (o) Gross profit is defined as revenue from services less direct operating expenses. The Company's gross profit excludes allocated depreciation and amortization expense. Gross profit margin is calculated by dividing gross profit by revenue from services.
- (p) FTEs represent the average number of Nurse and Allied Staffing contract personnel on a full-time equivalent basis.
- (q) Average revenue per FTE per day is calculated by dividing the Nurse and Allied Staffing revenue per FTE by the number of days worked in the respective periods. Nurse and Allied Staffing revenue also includes revenue from the permanent placement of nurses.
- (r) Days filled is calculated by dividing the total hours invoiced during the period by 8 hours. This method does not reflect the impact of revenue generated from permanent placements, reimbursed expenses, discounts and allowances, and the impact from accruals and adjustments recorded for financial statement purposes.
- (s) Revenue per day filled is calculated by dividing revenue invoiced by days filled for the period presented.

CONTACT:

Cross Country Healthcare, Inc. William J. Grubbs, 561-237-6202 President and Chief Executive Officer wgrubbs@crosscountry.com